Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 234,859,393 papers from all fields of science
Search
Sign In
Create Free Account
canakinumab 180 MG Injection [Ilaris]
Known as:
CANAKINUMAB 150 mg in 1 mL SUBCUTANEOUS INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION [Ilaris]
, ILARIS 180 MG Injection
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
7 relations
Histidine
Injection
Polysorbate 80
Sucrose
Expand
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Review
2017
Review
2017
Canakinumab (ILARIS®) in cryopyrin-associated periodic syndrome (CAPS)patients below 2 years of age: Review of four cases and literature.
D. Vana
2017
Corpus ID: 4147550
Cryopyrin-Associated Periodic Syndrome (CAPS) is combination of different autoinflammatory hereditary disorders with same genetic…
Expand
2014
2014
Опыт применения ингибитора интерлейкина 1β канакинумаба у больного с хронической тофусной подагрой
Array С. Елисеев
,
Array Желябин
,
Array Г. Барскова
,
A. Насонов
RSP
2014
Corpus ID: 59925804
This article reports a clinical case of administration of canakinumab (Ilaris®), an interleukin-1β inhibitor, in a patient with…
Expand